Bryostatin-1 (Bryo-1), a natural macrocyclic lactone, is clinically used as an anti-cancer agent. In this study, we demonstrate for the first time that Bryo-1 acts as a Toll-like receptor 4 (TLR4) ligand. Interestingly, activation of bone marrow-derived dendritic cells (BMDCs) in vitro with Bryo-1 led to a TLR4-dependent biphasic activation of nuclear factor-κB (NF-κB) and the unique induction of cytokines (IL-5, IL-6 and IL-10) and chemokines including regulated upon activation, normal T cell expressed and secreted RANTES and macrophage inflammatory protein 1 α (MIP1-α). In addition, electrophoretic mobility shift (EMSA) analysis demonstrated that Bryo-1 mediated induction of RANTES was regulated by NF-κB and the interferon regulatory factors (IRF) -1, IRF-3 and IRF-7 to the RANTES independently of myeloid differentiation primary response gene-88 (MyD88) gene. Bryo-1 was able to induce the transcriptional activation of IRF-3 through the TLR4/MD2-dependent pathway. In vivo administration of Bryo-1 triggered a TLR-4-dependent T helper cell 2 (Th2) cytokine response and expanded a subset of myeloid 
SUMMARY
Bryostatin-1 (Bryo-1), a natural macrocyclic lactone, is clinically used as an anti-cancer agent. In this study, we demonstrate for the first time that Bryo-1 acts as a Toll-like receptor 4 (TLR4) ligand. Interestingly, activation of bone marrow-derived dendritic cells (BMDCs) in vitro with Bryo-1 led to a TLR4-dependent biphasic activation of nuclear factor-κB (NF-κB) and the unique induction of cytokines (IL-5, IL-6 and IL-10) and chemokines including regulated upon activation, normal T cell expressed and secreted RANTES and macrophage inflammatory protein 1 α (MIP1-α). In addition, electrophoretic mobility shift (EMSA) analysis demonstrated that Bryo-1 mediated induction of RANTES was regulated by NF-κB and the interferon regulatory factors (IRF) -1, IRF-3 and IRF-7 to the RANTES independently of myeloid differentiation primary response gene-88 (MyD88) gene. Bryo-1 was able to induce the transcriptional activation of IRF-3 through the TLR4/MD2-dependent pathway. In vivo administration of Bryo-1 triggered a TLR-4-dependent T helper cell 2 (Th2) cytokine response and expanded a subset of myeloid dendritic cells that expressed a CD11c high CD8α -CD11b + CD4 + phenotype. The current study demonstrates that Bryo-1 can act as a TLR4 ligand and activate innate immunity. Moreover, the ability of Bryo-1 to trigger RANTES and MIP1-α suggests that Bryo-1 could potentially be used to prevent HIV-1 infection. Finally, induction of a Th2 response by Bryo-1 may help treat inflammatory diseases mediated by Th1 cells. Together, our studies have a major impact on the clinical use of Bryo-1 as an anti-cancer and immunopotentiating agent.
INTRODUCTION
Activation of the innate immune response is essential to control the initial stage of pathogen invasion and for the establishment of adaptive immunity (1) . Dendritic cells (DCs) play a critical role in the balance between immunity and immunological tolerance (2) due to their uniqueness as cells highly specialized in the uptake, transport, processing and presentation of antigens (3) . The discrimination process leading to cell immunity or tolerance is highly regulated by pattern recognition receptors (PRRs), such as the Toll-like receptor (TLR) family, which recognize pathogen-associated molecular patterns (PAMPs) (1, 4) . Immature DCs express many members of the TLR family (5) . Recognition of PAMPs by DCs results in the activation of TLR family members, which in turn activate the NF-κB and mitogen-activated kinase (MAPK) signaling pathways and induce DC maturation (6, 7) . Upon maturation, DCs acquire the ability to produce a wide range of cytokines/ chemokines and promote the differentiation of various T helper cell phenotypes such as Th1, Th2, Th17, and Tregs, thereby controlling the activation of adaptive immune responses (6, 8) .
The TLR family is the essential recognition and signaling component of the host defense (9, 10) . DCs express TLR4, which mediates the recognition of Gram negative bacterial LPS and several other PAMPs (11) . Toll signaling to NF-κB occurs from the conserved Toll-IL-1-resistance (TIR) domain of TLR, which triggers the recruitment of the TIRdomain containing adaptor protein MyD88 (9) . The recruitment of MyD88 to the activated TLR results in NF-κB activation via the MyD88 adaptor-like protein (Mal/TIRAP) (12) and the IκB kinase (IKK) complex (13) . While most of the TLRs seem to be exclusively dependent on the expression of MyD88 for all their functions, TLR3 and TLR4 are unique in that they are capable of activating both MyD88-dependent and MyD88-independent responses (9, 14) , through the TIR domain-containing adaptorinducing IFN-β (TRIF) (15) . It has been shown that stimulation of DC maturation and the induction of type 1 interferon (IFN-β) is mediated by the MyD88-independent signaling pathway (14, 15) . However, while all TLRs activate NF-κB, not all TLRs induce IFN-β (8) . Therefore, TIR-domain containing adaptors such as MyD88, TRIF and Mal/TIRAP play crucial roles in TLR-signaling pathways, because they provide specificity to the response generated by signaling through each TLR (16) .
Bryostatin-1 (Bryo-1) is a macrocyclic lactone isolated from the marine bryozoan, Bugula neritina (17) . The potent anti-proliferative effects and antineoplastic properties of Bryo-1 against various tumor cells have led to its use as a chemotherapeutic agent. Recently, Bryo-1 has received much attention because of its immunomodulatory properties, both in vitro and in vivo. Bryo-1 has been shown to be a potent activator of human macrophages (18) and also to induce the production of immunomodulatory cytokines-IL-1, IL-6, IL-8, and TNF-α (18) . It is also known that Bryo-1 induces the proliferation and activation of B and T cells (19, 20) . Studies from our laboratory have shown that Bryo-1 enhances the maturation and antigen-presenting abilities of DCs in vitro (21) . We have demonstrated that Bryo-1 alone or in combination with calcium ionophore could activate cord-blood monocyte derived DCs to express higher levels of MHC Class II antigens, as well as, the co-stimulatory molecules CD1a, CD80, CD83, and CD86. Furthermore, Bryo-1 and calcium ionophore activated DCs were capable of inducing the proliferation of cord blood derived alloreactive T cells and the production of IFN-γ (21). However, the molecular mechanism(s) by which Bryo-1 exerts its biological properties on DCs is not clearly understood. In this study, we investigated the involvement of TLR4 in Bryo-1 mediated effects in vitro and in vivo.
In the current study, we have identified some unique properties of Bryo-1 which demonstrate that it can act as a TLR-4 ligand, thereby activating the innate immunity. Our findings are important and have major translational impact because Bryo-1 is currently being tested in humans as an anti-cancer agent. Furthermore, the ability of Bryo-1 to induce CC-chemokines, RANTES and MIP-1-α may have a major application as an inhibitor of HIV infection. Moreover, the inability of Bryo-1 to activate inflammatory cytokines such as IL-12 in DCs and its property to promote a Th2 response may find its use to treat inflammatory diseases by facilitating Th1 to Th2 switch.
EXPERIMENTAL PROCEDURES
Mice-Adult (6 to 8 weeks of age) female C57BL/6 (H-2 b ) (referred to as wild-type (WT), and C57/10ScNJ (H-2 b ) (referred to as TLR4 -/-or TLR4 KO) mice were purchased from The National Cancer Institute and Jackson laboratories, respectively. MyD88 -/-mice were kindly provided by Dr. Wei Chao, Department of Anesthesia and critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Mice were housed in polyethylene cages and given standard animal feed and water ad libitum. Mice were housed in rooms maintaining a temperature of 74 ± 2°F and on a 12-h light/dark cycle. cell lines stably  expressing pcDNA3, TLR3, TLR4 or both TLR4  and MD2 were gifts from D. Golenbock (The University of Massachusetts Medical School, Worcester, Massachusetts). All cell lines were maintained in DMEM supplemented media as described (11 -/-mice were treated with Byro-1 (10 ng/ml) for 24 h, in vitro after which the cells were spun down and the supernatants collected. Supernatants from LPS (100 ng/ml) and vehicletreated BMDCs were used as positive and negative controls. For serum samples, blood was drawn at 24 h after Bryo-1(75μg/kg body weight) and serum separated. Vehicle treated and untreated mice were used as controls. The serum was assayed using the multiplex bead-based assays (Bio-plex assay, BioRad), designed to quantitate multiple cytokine analysis, as described (23) . We looked at a panel of 18 cytokines and chemokines, including IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12(p40), IL-12(p70), IL-17, G-CSF, GMCSF, TNF-α, IFN-γ, KC, MIP-1α, and RANTES.
Stable Cell Lines-HEK293
ELISA-The supernatants from the cultures were harvested and analyzed using ELISA kit for the production of RANTES (Peprotech Inc., NJ) and IFN-β (PBL Biomedical Laboratories, NJ).
Electrophoretic mobility shift assay-BMDCs from WT and TLR4 KO mice were obtained as described above and subsequently treated with either LPS (100 ng/ml) or Bryo-1 (10 ng/ml). At the indicated times, nuclear extracts were prepared as previously described (24) and electrophoretic mobility shift analysis was performed probing for the DNA binding activity of NF-κB. Briefly, 5 μg of nuclear extract was incubated with 1 μg of poly (dIdC)-poly (dI-dC) (Amersham Biosciences) for 10 minutes at room temperature. To this mixture, 2x10 4 cpm of a P 32 -labeled oligonucleotide (NF-κB: 5'-ATGTGAGGGGACTTTCCCAGGC-3', Santa Cruz Biotechnology; RANTES-ISRE-IRF-1-RE: 5'-ACACAAAATGGAAAACTGAAATCACCCTTG G-3' and IFNβ-PRD III-I: 5'-GAAAACTGAA AGGGAGAAGTGAAAGTG-3', Integrated DNA Technologies), was added (binding site is underlined) in a buffer consisting of 4 mM Tris-HCl, pH 7.9, 12 mM Hepes-KOH, 60 mM KCl, 12% glycerol, 0.5 mM EDTA and 1 mM dithiothreitol and incubated for an additional 20 minutes. Complexes were resolved on a non-denaturing 5% polyacylamide gel and subsequently exposed on Hyperfilm (Amersham Pharmacia Biotech). For supershifts, antibodies raised against specific subunits of NF-κB: p65, p50 (NLS), c-Rel, RelB or the IRF family members: IRF-1, IRF-3 (H-246), IRF7 (FL-425) (Santa Cruz Biotechnology), were pre-incubated for 10 minutes at room temperature before the addition of 1 mM phenylmethylsulfonyl fluoride and 1 μg of poly (dI-dC)-poly (dI-dC).
Luciferase Reporter Gene Assays-HEK293 cells (1x10 6 ) were seeded into 6-well plates and transiently transfected 24 h later using lipofectamine transfection reagent (Invitrogen), following the recommendations of the manufacture. For NF-κB and IFNβ reporter assays, cells were transfected with 0.5 μg of either ELAM or IFNβ, respectively and 0.1 μg of CMV-β-Gal reporter vectors. For IRF-3 reporter assay, HEK293 cells (4x10 4 ) were seeded into 96-well plates and transfected with 40 ng/well of the Gal4-luciferase reporter gene. At 36 h following transfection, cells were treated with bryo-1 (50 ng/ml), LPS (100 ng/ml), for 6 h or left untreated. Cell lysates were prepared and reporter gene activities were measured using the dualluciferase reporter system (Applied Biosystems). Data was normalized for transfection efficiency and expressed as the mean relative stimulation ± SD.
Detection of RANTES in DCs from Myd88-/-mice-To detect expression of RANTES in DCs from
Myd88-/-mice, we performed intracellular staining using BD Cytofix/Cytoperm TM Fixation/ Permeabilization kit followingthe recommendations of the manufacturer (BD Biosciences, San Diego, CA).
Western blot analysis of IRF3-Western blotting was performed using antibodies against total IRF3 and phosphorylated IRF3 (P-IRF3 Ser396; Santa Cruz Biotechnology) at a dilution of 1:1000, and β-actin at dilution of 1:5000. HRP-conjugated secondary Ab was used at 1:4000 dilution (Cell Signaling). In brief, lysates from vehicle-or Bryo-1-treated BMDCs were prepared and protein concentration was measured using standard Bradford assay (BioRad, WI). The proteins fractionated in SDS-PAGE were transferred onto PVDF membranes using a dryblot apparatus (BioRad, Hercules, CA). The membrane was first incubated in blocking buffer for 1 hr at RT, followed by incubation in primary antibody at 4°C overnight. The membrane was incubated for 1 hr in HRP-conjugated secondary antibody (Cell Signaling Technology, Danvers, MA) in blocking buffer after washing 3 times (10-15 min) with washing buffer (PBS + 0.2% Tween 20) . The membranes were incubated in developing solution (ECL Western Blotting Detection Reagents, GE Life Sciences, England) and signal was detected using ChemiDoc System (BioRad). Densitometric analyses of the Western blots were performed using ChemiDoc software (BioRad).
Statistical Analysis-The statistical comparisons between different study groups were carried out using Student's t test and GraphPad software and differences of P < 0.05 were considered to be significant. Each experiment was repeated at least three times.
RESULTS

Treatment of BMDCs with Bryo-1 in vitro leads
to TLR4-dependent expression of chemokines, cytokines and upregulation of co-stimulatory molecules-Earlier studies from our laboratory have shown that Bryo-1 is capable of inducing maturation of DCs (21). To determine the cytokine/chemokine profile induced by Bryo-1, immature BMDC from WT and TLR4 -/-mice were treated with Bryo-1 or vehicle. Next, supernatants were evaluated for the presence of cytokines and chemokines by ELISA, as described in Experimental Procedures. Specifically, we studied cytokines and chemokines that are induced following activation of DCs through TLRs, including IL-1α  IFN-β, IFN-γ, IL-12, TNF-α, IL-6, MIP-1-α, KC, and RANTES. We observed that activation of BMDCs with LPS from WT mice led to significant induction of IL-12 and IL-1α as well as low levels of IFN-β ( Fig. 1) and furthermore, these cytokines were dramatically reduced in LPSactivated BMDCs from TLR4 KO mice. Interestingly, Bryo-1 activated BMDCs produced little or no IL-12 and IL-1α  and low levels of IFN-β . Moreover, of all the cytokines and chemokines screened, Bryo-1 activated BMDCs from wild-type mice produced only MIP-1α and Regulated upon Activation, Normal T-cell Expressed and Secreted (RANTES; also known as CCL5) (Fig. 1) . It was noted that Bryo-1-induced production of IFN-β, MIP-1α, and RANTES in DCs was significantly higher in WT BMDCs when compared to BMDCs from TLR4 -/-mice, suggesting that the induction of IFN-β, MIP-1α, and RANTES by Bryo-1was also regulated, at least in part, through TLR4 activation.
Bryo-1 induces NF-κB activation through TLR-4-
Because all TLR signaling pathways culminate in the activation of NF-κB transcription factor, which in turn regulates the induction of cytokines, we investigated whether Bryo-1-induced activation of DCs involved modulation of NF-κB binding activity. To explore this possibility, nuclear extracts from Bryo-1 (10 ng/ml) or LPS (100 ng/ml) stimulated BMDCs were prepared and the NF-κB binding activity was examined by EMSA analysis, using a specific 32 P-labeled NF-κB oligonucleotide. As shown in Fig. 2A , Bryo-1 induced NF-κB activation at 2 h and 4 h following treatment. We used LPS-treated BMDCs as a positive control. To further evaluate the composition of the NF-κB complexes induced by Bryo-1, supershift analysis using antibodies against the NF-κB members p50, p65, c-Rel, and RelB was performed. As shown in Fig. 2B , majority of the NF-κB complexes were composed of a p50 homodimer after a 2 h treatment with Bryo-1, and of p50/c-Rel and p50/p65 heterodimers following a longer (4 h) incubation time with Bryo-1. To determine the binding specificity of these complexes, competition analysis using a mutated NF-κB oligonucleotide was performed. As shown in Figs. 2C-D, binding of the nuclear complexes to the DNA probe was specific since Bryo-1-mediated stimulation of DNA-protein complexes was not blocked by excess of unlabeled mutated NF-κB oligonucleotide (lane 9). Competition assays using 100-fold molar excess of unlabeled DNA probe as specific competitor further demonstrated the specificity of the band corresponding to NF-κB (Fig 2E: cold probe, lane 4).
To determine if TLR4 was implicated in Bryo-1-mediated activation of NF-κB, we examined the ability of BMDC nuclear extracts from C57BL/6 and TLR4 -/-mice to bind to the NF-κB probe in response to Bryo-1. Interestingly, we found that the NF-κB binding activity of nuclear extracts from TLR4 -/-BMDCs was significantly reduced relative to that of wild-type cells suggesting that TLR4 was in fact involved in Bryo-1 signaling in BMDCs (Fig. 3) .
Bryo-1-mediated induction of RANTES is regulated by transcription factors, NF-κB and IRFs-
We next addressed the molecular mechanism(s) by which Bryo-1 triggers the production of RANTES by DCs. In order to determine if the increased RANTES production induced by Bryo-1 is mediated by IRFs, the binding of nuclear extracts from Bryo-1 or vehicle treated BMDCs to a 32 P-labeled oligonucleotide containing the IRF-binding motif in the RANTES gene promoter was examined by EMSA analysis, as previously described (24) . As in LPS-stimulated BMDCs, binding of nuclear extracts to the IRF motif of the RANTES promoter was observed in response to Bryo-1 treatment of BMDCs (Fig. 4A) . Furthermore, supershift analysis of the IRF complexes, using antibodies against the IRF-1, IRF-3 and IRF-7 proteins, revealed IRF-1 as the protein bound to the RANTES promoter in both Bryo-1 and LPS stimulated BMDCs (Fig. 4A) . Interestingly, IRF-3 (lanes 8, 12) and IRF-7 (lanes 9, 13) also caused a gel shift when compared to the binding activity induced by Bryo-1 in the absence of antibody (Fig. 4A , lanes 6 and 10) at both time points (2 h and 4 h) suggesting that IRF-1 and possibly IRF-3 and IRF-7 may be the modulators of Bryo-1-mediated RANTES gene expression.
NF-κB inhibitors decrease Bryo-1 induced NF-κB binding activity-The promoter of the RANTES gene carries IRF and NF-κB cis-acting elements both of which may be critical for RANTES gene expression (25) . To further examine the specificity of Bryo-1-mediated increase in NF-κB binding activity, a series of proteosome inhibitors were used. Briefly, DCs were pre-incubated for 2 h with the NF-κB inhibitors ALL (10 μM), MG132 (1 μM), TAT-NBD peptide (200 μM) or left untreated followed by Bryo-1 treatment for 4 h. DCs were harvested for nuclear extract preparation and the supernatant collected for cytokine analysis by ELISA, as described in Experimental Procedures. The nuclear extracts were examined for their ability to bind to a 32 P-labeled oligonucleotide containing the NF-κB consensus sequence. In the presence of nuclear extracts from vehicle treated BMDCs, constitutive NF-κB complex formation was observed (Fig. 5, lane 2) . Bryo-1 treatment however, further increased protein complex binding to the NF-κB site (Fig. 5, lane 4) . Pre-incubation of BMDCs with various NF-κB inhibitors resulted in a decreased DNA binding activity of nuclear extracts relative to that of Bryo-1 alone. Furthermore, the NF-κB inhibitors ALL and NBD peptide were more effective at reducing protein-DNA complexes formation than MG132 under our experimental conditions.
In addition, the supernatants were also collected and analyzed for the presence of RANTES by ELISA (Fig. 5B) . It was noted that Bryo-1-mediated induction of NF-κB binding activity was considerably decreased in the presence of the proteosome inhibitors, ALL, TAT-NBD peptide and to a lesser extent MG132. In addition, pre-incubation of BMDCs with the NF-κB inhibitors resulted in a decrease in the amount of RANTES chemokine released into the medium (Fig. 5B) , suggesting that NF-κB was involved in the production of RANTES. Altogether, these data indicated that NF-κB and IRF-1 may be involved in the induction of RANTES in BMDCs in response to Bryo-1 stimulation.
Role of MyD88 in RANTES production following activation of BMDCs by Bryo-1-TLR4
activates both the MyD88-and the TRIF-dependent pathways. To investigate further, the role of MyD88, immature BMDCs from WT and MyD88-deficient mice were cultured with Bryo-1 and analyzed for intracellular RANTES induction.
The data indicated that BMDCs from MyD88 KO mice produced significant levels of RANTES comparable to the WT mice thereby suggesting that Bryo-1-induced RANTES production was independent of MyD88 ( Fig. 6) . These data were also consistent with the above observation that RANTES induction by Bryo-1 involved IRFs whose activation is independent of MyD88.
Role of TLR-4 in Bryo-1-mediated induction of IFN-β in DCs-
There is increasing evidence that supports a key role for DCs in the production of type I interferons and the regulation of innate and adaptive immune responses (26, 27) . We noted that activation of DCs with Bryo-1 failed to induce majority of the cytokines characteristic of DCs except low levels of IFN-β. To further corroborate the role played by TLR-4 in the induction of IFN-β by Bryo-1, EMSA analysis of nuclear extracts from Bryo-1 (10 ng/ml) or LPS (100 ng/ml) stimulated WT or TLR4 -/-BMDCs using a specific 32 P-labeled DNA oligonucleotide containing the positive regulatory domains (PRDI-III) of the IFN-β gene promoter was performed. The data demonstrated that while Bryo-1 induced the binding of nuclear complexes to the IFN-β promoter DNA probe in the WT cells, Bryo-1-mediated stimulation of DNAprotein complex formation was significantly reduced and delayed in TLR4 -/-BMDC (Fig. 7) . These data suggested that TLR-4 was involved in the induction of IFN-β by Bryo-1, consistent with the observation that TLR4 deficient BMDC produced decreased levels of IFN-β upon Bryo-1 activation when compared to wild-type BMDC (Fig. 1) .
Bryo-1 induces transcriptional activation of IRF-3 via
TLRs-To determine whether Bryo-1 activates the transcription factor IRF-3 through TLRs, we used an in vivo assay for IRF-3 activation, in which a hybrid protein consisting of the yeast Gal 4 DNA-binding domain (DBD) is fused to the IRF-3 (Gal4-IRF-3) lacking its own DNA-binding domain (28) . Transcriptional activation of the Gal4 reporter gene requires activation of IRF-3 (28) . When TLR3, TLR4MD2 or TLR4-expressing HEK293 cell lines were transfected with vectors encoding a luciferase reporter gene containing the Gal4 upstream activation sequence and either a vector encoding Gal4-DBD or Gal4-IRF-3 followed by 8 h stimulation with Bryo-1, the Gal4 reporter gene was activated. Bryo-1 induced increases in luciferase activity in both TLR3 and TLR4/MD2 but not TLR4 (Fig. 8A) . Taken together, these results suggested that TLRs are involved in Bryo-1-mediated activation of IRF-3. To further explore this possibility, the expression levels of total IRF-3 and phosphorylated IRF-3 (P-IRF3 Ser396) were determined in BMDCs cell lysates from C57BL/6 (TLR4+/+) and TLR4 KO (TLR4-/-) mice in the absence or presence of Bryo-1. As shown in Fig 8B- C, Bryo-1 stimulation led to increased phosphorylation of IRF-3 in BMDCs at both 2h and 4h post-treatment, when compared to vehicle-treated BMDCs. There were no changes in total IRF-3 in vehicle-or Bryo-1-treated BMDCs. However, there was no phosphorylation of IRF-3 in BMDCs generated from TLR4 KO mice in the presence of Bryo-1. These data demonstrate that Bryo-1 may activate IRF-3 via TLR4 in BMDCs (Fig. 8B-C) .
Bryo-1 treatment in vivo leads to TLR4-dependent Th2 cytokine production-We next tested if administration of Bryo-1 would trigger cytokine production in vivo and if this would also be regulated by TLR4. To this end, serum collected from WT and TLR4 -/-mice, 24 h following treatment with Bryo-1 or vehicle was assayed for 18 different cytokines/chemokines, including IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12(p40), IL-12(p70), IL-17, G-CSF, GMCSF, TNF-α, IFN-β, KC, MIP-1α, and RANTES. Surprisingly, WT mice receiving Byro-1 demonstrated induction of only certain Th2 cytokines, IL-5, IL-6, IL-10, and the chemokines, MIP-1-α and keratinocyte-derived chemokine (KC), when compared to vehicle-treated mice (Fig. 9) . In contrast, TLR4 -/-mice failed to produce significant levels of these cytokines and chemokines following Bryo-1 injection (Fig. 9) .
Phenotype of DCs expanded in vivo by Bryo-1-The type of cytokine(s) produced early in an immune response is key in determining if a Th1 or Th2-like immune response is generated. The subsets of DC are thought to be important in influencing the type of response (29, 30) . To this end, WT mice were injected with Bryo-1 and the splenocytes were examined for the various DC lineage markers. Cells were double-stained for CD11c and CD11b, B220, CD4 and CD8α. Flow cytometric analysis demonstrated that there was a significant increase in the CD11c + CD11b + cell population in the Bryo-1 treated group when compared to the vehicle control (Fig. 10A) . The CD11c + B220 + cell population was not enhanced significantly in the Bryo-1 treated group (data not shown). The spleen cells were also triple stained for CD11c, CD4 and CD8α. Our results demonstrated an increase in the CD11c + CD4 + (Fig. 10B) population in the Bryo-1 treated group but no increase in the CD11c + CD8α + population (data not shown). The total cellularity of CD11b+ and CD4+ DCs in the spleen was higher in the Bryo-1 treated groups when compared to the vehicle treated group (Fig. 10C) . Taken together with the earlier lineage marker data, these findings indicated that Bryo-1 may expand a subset of the myeloid arm of DCs that are CD11c + CD8 +-CD11b + CD4 + .
Upregulation of various DC co-stimulatory molecules (CD40, CD80, and CD86) and chemokine (RANTES) are
Bryo-1-specific-As shown by us in the current and previous study, LPS-induced activation of DCs showed a distinct pattern when compared to that induced by Bryo-1 (21). To further rule out the possibility that the effect of Bryo-1 may have been mediated by low levels of endotoxin contamination, we investigated the effect of LPS and Bryo-1 on DC maturation and RANTES production in the presence of polymixin B, which is known to block LPS -mediated effects. To this end, BMDCs generated from C57BL/6 mice were cultured in the presence of vehicle, Polymixin B sulphate (PB; 10 nM) alone, Bryo-1 (10 nM), Bryo-1 + PB, various doses of LPS (0.1, 1, and 10 nM), and LPS + PB for 24 h in a 96-well plate. Next, the cells were stained for CD40, CD80, and CD86 and the supernatants from cultures were examined for RANTES production. The data showed that Bryo-1 caused the maturation of DCs with a significant increase in the expression of CD40, CD80, and CD86 when compared to vehicle-treated groups (Fig. 11 A-C) , as noted in our earlier studies (21). However, we did not observe downregulation of these markers in the presence of PB in Bryo-1 (Bryo-1 + PB)-treated groups. LPS, when used alone, failed to induce DC maturation at 1 nM, but was able to upregulate the expression of CD40, CD80, and CD86 at 1 and 10 nM. However, at 10 nM, LPS was not as effective as 10 nM of Bryo-1 (Fig. 11 A-C) . Furthermore, addition of PB to LPS cultures caused complete inhibition of upregulation of all markers induced by LPS (Fig. 11 A-C) . Also, similar results were observed when RANTES expression was analyzed in various cultures of DCs. LPS caused a dose dependent increase in RANTES production and PB completely inhibited RANTES induction by all doses of LPS tested. In contrast, PB failed to significantly inhibit Bryo-1-induced RANTES (Fig.  11 D) . Together, these data suggested that Bryo-1-induced activation of DCs was independent of LPS contamination.
DISCUSSION
Bryostatin 1 is a macrocyclic lactone that is known to regulate PKC activity (31) . It has been shown to inhibit cell growth and angiogenesis, promote apoptosis, and induce cancer cell differentiation because of which it is being screened as an anticancer agent in humans (32), Our lab has previously shown that Bryo-1 promotes maturation of murine and human DCs and such DCs act as very potent APCs, better than LPS-activated DCs, to induce T cell proliferation (21). In this study, we demonstrate for the first time that Bryo-1 activates DCs through TLR4. Moreover, we report that stimulation of BMDCs by Bryo-1 resulted in the stimulation of NF-κB binding activity. The NF-κB DNA binding activity was significantly decreased in BMDCs from TLR4 -/-mice, suggesting that Bryo-1 induction of NF-κB binding activity is TLR4-signal mediated. Interestingly, unlike LPS, Bryo-1 induced a biphasic activation of NF-κB. The initial phase, which occurred 2 h after Bryo-1 treatment, was characterized by the formation of p50 homodimers, which are associated with a repressor function. By 4 h, the composition of the DNA-protein complexes switched to p50/c-Rel and p50/p65 heterodimers, which are the transcriptionally active complexes. Although the functional implications of these findings will require additional studies, it is possible that the distinct NF-κB complexes formed in response to Bryo-1 may have a role in the differential regulation of gene expression in BMDCs, as well as, in the control of DC-mediated immune and inflammatory responses.
It is well established that TLR4 signals through at least four adaptor molecules known as TIRAP, MyD88, TRAM and TRIF. They associate with a diverse repertoire of signaling components and they constitute the platforms for the initiation of different signaling pathways. It has been shown that LPS stimulation of TLR4 can activate the NF-κB signaling pathway by (i) oligomerization of MyD88 (9, 26) , which induces the recruitment and activation of IL-1 receptor activated kinase (IRAK) 1 and IRAK4, or via (ii) TRAM-TRIF adaptor molecules, which induce activation of NF-κB independently of MyD88. Early stimulation of NF-κB activity by TLR4 activation, results in the production of proinflammatory cytokines, is regulated through the MyD88-dependent pathway (6, 33 ). In the current study, we noted that Bryo-1 activated BMDCs produced RANTES independent of MyD88 thereby suggesting that NF-κB activation in response to Bryo-1 may be MyD88-independent. Our studies show that like LPS, Bryo-1 stimulation of TLR4 induced IFN-β production ( Fig 7B) and increased binding activity to the IFN-β gene promoter ( Fig  7A) . However, the binding activity was significantly reduced and delayed in BMDCs from TLR4 -/-mice. Similarly, IFN-β production was markedly decreased in the supernatant of Bryo-1 treated TLR4 -/-DCs.
Furthermore, gene-targeting experiments have shown that LPS-mediated production of IFN-β through TLR4 occurs mostly, if not entirely, independent of MyD88 (25) but is dependent on the adaptor molecules, TRAM/TRIF (34, 35) . It has recently been reported that the IRF-3 transcription factor is a key regulator of this pathway (26) . Activation of IRF-3, by gene reporter assays, was observed following Bryo-1 stimulation of TLR4/MD2 HEK293-expressing cells. These results, together with a delay in the activation of NF-κB and the lack of pro-inflammatory cytokine production by Bryo-1 stimulation, begins to support the premise that Bryo-1 may be signaling through the MYD88-independent pathway of TLR4.
We also analyzed the binding activity of several IRF transcription factors to the promoter response elements of the RANTES gene. We observed that, in addition to increasing IFN-β production and activating NF-κB and IRF-3 transcription factors, Bryo-1 was able to induce DNA binding of the transcription factors IRF-1, IRF-3 and IRF-7 to the RANTES-IRF-1 site of the gene promoter. Furthermore, treatment of DCs with various NF-κB inhibitors prior to Bryo-1 stimulation, not only partially decreased the DNA binding activity by EMSA analysis, but resulted in a significant decrease in the production of the chemokine, RANTES (Fig 6) , suggesting that Bryo-1-mediated production of RANTES requires a functional TLR4 and may be regulated by NF-κB and IRF transcription factors. Consistent with our findings, Lee and co-workers have shown that NF-κB and IRF-1 cooperatively activated the RANTES promoter in co-transfection studies and suggested that activation of the RANTES promoter by NF-κB and IRF-1 may occur through a multi-protein complex formation, as previously described (42) . In addition, Kirchhoff and co-workers have shown that IRF-1 could activate NF-κB, which then synergized with IRF-1 to induce IFN-β gene expression (36) . Expression of the RANTES gene has been demonstrated to be stimulated by inflammatory cytokines (37, 38) , LPS (39), T cell activation (40) and viral infection (41, 42) . Recently, it has been demonstrated that IRF-3 plays a key role in the activation of RANTES transcription by viral infection (43) . Interestingly, in these studies the promoter element recognized by IRF-3 mapped to the same region as the IRF-1 binding site, identified by Lee and co-workers (44) . These findings support our observation that IRF-3 and potentially IRF-7 bound to the IRF-1 response element of the RANTES promoter. IRF-3 and IRF-7 are known to be key activators of the RANTES gene (43) , suggestive of the induction of a subset of myeloid DCs. These data are also consistent with our observation that such Bryo-1-activated DCs failed to produce IL-12 but induced significant levels of Th2 cytokines in vivo such as IL-5, IL-6 and IL-10. These cytokines are known to be anti-inflammatory and to increase antibody response.
Activation of murine BMDCs through various TLRs have been shown to induce a variety of chemokines such as MIP-1α, MIP-1β, MCP-1, RANTES and KC (46) . In the current study, we noted that Bryo-1 induced high levels of MIP-1α and RANTES production by the DCs when compared to LPS. Moreover, the production of these chemokines was significantly decreased in TLR4 deficient mice.
RANTES, also termed CCL5, is a proinflammatory CC-chemokine that plays multiple roles during inflammation. RANTES displays high affinity binding and signaling through multiple independent chemokine receptors including CCR1, CCR3, and CCR5. Also, MIP-1 belongs to CC-chemokine subfamily consisting of MIP-1α (CCL3), MIP-1β (CCL4), MIP-1δ (CCL9/10) and MIP-1γ (CCL15) that are produced by many cells, including DCs. MIP-1 proteins, act via G-protein-coupled cell surface receptors CCR1, CCR3, and CCR5. Because of their ability to bind such chemokine receptors, RANTES and MIP-1 are considered to be the most potent natural inhibitor of HIV-1 infection and are currently being pursued as safe and effective viral entry inhibitors (47, 48) . Our findings raise an exciting possibility of the potential use of Bryo-1 as an inhibitor of HIV-1 infection.
Bryo-1 is well known for its anti-tumor activity which has been ascribed to modulation of protein kinase C (PKC) activity. Clinical trials have suggested that Bryo-1 does not exhibit significant toxic effects such as myelosuppression, gastrointestinal toxicity or neuropathy, except for myalgia (49, 50) . In the clinical trials, Bryo-1 was also shown to induce IL-6 and TNF-α (50) . The current study has a major translational impact on the clinical use of Bryo-1 because it demonstrates for the first time that Bryo-1 may act as a TLR-4 ligand and may serve as a potent activator of innate immunity, which could be beneficial to trigger antitumor immunity. Moreover, the ability of Bryo-1 to promote a Th2 response in vivo may help treat clinical disorders that are mediated by Th1 inflammatory cells. 
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